Tag: ABS-1230
-
Jazz Bets $1.32 Billion on a Precision Therapy for Rare Epilepsy
Jazz is acquiring Actio Biosciences for up to $1.32 billion, gaining ABS-1230, a precision therapy targeting KCNT1-related epilepsy.
Jazz is acquiring Actio Biosciences for up to $1.32 billion, gaining ABS-1230, a precision therapy targeting KCNT1-related epilepsy.